摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-2-yl] acetate | 95720-37-9

中文名称
——
中文别名
——
英文名称
[(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-2-yl] acetate
英文别名
——
[(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-2-yl] acetate化学式
CAS
95720-37-9
化学式
C23H32O4
mdl
——
分子量
372.505
InChiKey
TUZDSTXFAGZENH-WYIHNHJISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    60.4
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Oxidation of enones to α′-acetoxyenones using manganese triacetate
    作者:Norma K. Dunlap、Mark R. Sabol、David S. Watt
    DOI:10.1016/s0040-4039(01)81699-3
    日期:1984.1
    The oxidation of α,β-unsaturated ketones with manganese (III) triacetate in benzene furnishes α'-acetoxyenones in good yields.
    三乙酸(III)在苯中氧化α,β-不饱和酮可提供高产量的α'-乙酰氧烯酮。
  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ("PNAs") with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    申请人:Becker L. Matthew
    公开号:US20060159619A1
    公开(公告)日:2006-07-20
    A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2′-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    一种功能性生物活性颗粒共轭物,用于诊断和治疗癌症,作为生物门户,包括与之相关联的细胞内靶向配体,包括PNA或其他核酸酶抵抗性寡核苷酸类似物,如MOE-mRNA(2'-甲氧基乙基mRNA)或LNA(锁定核酸),具有选择性结合于哺乳动物体内癌症或疾病状态特异性表达或过表达的mRNA序列。在一个方面,特异性过表达的靶点是unr mRNA,可以通过反义序列PNA50进行靶向。
  • Dispenser with dispersing member for delivering beneficial agent
    申请人:ALZA CORPORATION
    公开号:EP0297725A2
    公开(公告)日:1989-01-04
    A dispenser is disclosed for delivering a beneficial agent to an environment of use. The dispenser comprising a wall that surrounds an agent, push means for pushing the carrier means from the dispenser and fragmenting means for fragmenting the carrier as it is pushed from the dispenser.
    本发明公开了一种分配器,用于将有益药剂输送到使用环境中。分配器包括一个环绕药剂的壁、用于将载体从分配器中推出的推动装置和用于在载体从分配器中推出时将其破碎的破碎装置。
  • Dispenser with movable matrix comprising a plurality of tiny pills
    申请人:ALZA CORPORATION
    公开号:EP0300623A2
    公开(公告)日:1989-01-25
    A dispenser is disclosed for delivering tiny pills to an environment of use. The dispenser comprising a wall that surrounds an internal space comprising a first mean in the dispenser for changing from a dispenser state to an environment of use state on leaving the dispenser, tiny pills in the first means, and a second means in the dispenser for aiding in displacing the first means for the dispenser.
    本发明公开了一种向使用环境输送小药丸的分配器。分配器包括一个环绕内部空间的壁,该内部空间包括分配器中的第一装置,用于在离开分配器时从分配器状态变为使用环境状态;第一装置中的小药丸;以及分配器中的第二装置,用于帮助分配器移位第一装置。
  • Dosage form for time-varying patterns of drug delivery
    申请人:——
    公开号:US20030125714A1
    公开(公告)日:2003-07-03
    The present invention provides a multi-release oral drug delivery system that initiates drug release following an initial drug-free release interval, after administration to a subject, and a second drug-free release period before release of another dose of drug. The system has (1) inner compartments enclosed within a semipermeable membrane, and (2) a drug coating on the exterior of the semipermeable membrane surrounded by a microporous membrane, which microporous membrane is permeable to fluid and drug. The drug coating is released after the initial drug-free release interval. An inner compartment drug is released after a second drug-free release interval provided by a drug-free inner compartment.
    本发明提供了一种多重释放口服给药系统,该系统在给受试者用药后的初始无药释放间隔期和释放另一剂量药物前的第二个无药释放期后开始释放药物。该系统有:(1)封闭在半透膜内的内部隔室;(2)在半透膜外部的药物涂层,由微孔膜包围,微孔膜可渗透液体和药物。药物涂层在初始无药物释放间隔期后释放。内室药物在无药物内室提供的第二个无药物释放间隔期后释放。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B